Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.

@article{Kondo2008AdoptiveIF,
  title={Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.},
  author={Hiroshi Kondo and Shoichi Hazama and Toru Kawaoka and Shigefumi Yoshino and Shin Yoshida and Kazuhisa Tokuno and Motonari Takashima and Tomio Ueno and Yuji Hinoda and Masaaki Oka},
  journal={Anticancer research},
  year={2008},
  volume={28 1B},
  pages={379-87}
}
BACKGROUND Pancreatic cancer has a poor prognosis. The clinical efficacy of immunotherapy using both dendritic cells pulsed with MUC1 peptide (MUC1-DC) and, cytotoxic T lymphocyte (CTL) sensitized with a pancreatic cancer, YPK-1, expressing MUC1 (MUC1-CTL) was evaluated. PATIENTS AND METHODS Twenty patients with unresectable or recurrent pancreatic cancer were enrolled. Peripheral blood mononuclear cells (PBMCs) were separated into adherent cells for induction of MUC1-DCs and floating cells… CONTINUE READING